STOCKWATCH
·
Business UpdateMay 4, 2026, 01:31 PM

Catalyst Crew Pivots to AI Healthcare; New CEO Appointed

AI Summary

Catalyst Crew Technologies Corp. filed an amendment to its 2025 Annual Report, detailing a significant strategic pivot to AI-enabled healthcare technology solutions. This shift followed a change in control on February 17, 2026, where Kevin Rodan Levy acquired a controlling interest and was appointed CEO and sole director. The company subsequently acquired AI healthcare assets from Dr. Levy and a Venezuelan subsidiary, Inversiones Long 33, C.A., to support its new focus on Latin American markets. As a development-stage company, it reported no revenue for 2025 and 2024, and its auditor expressed substantial doubt about its ability to continue as a going concern.

Key Highlights

  • Catalyst Crew underwent a change in control on February 17, 2026.
  • Acquired AI healthcare technology assets from new CEO, Kevin Rodan Levy.
  • Kevin Rodan Levy appointed CEO, President, CFO, Secretary, Treasurer, and sole director.
  • Acquired Venezuelan subsidiary, Inversiones Long 33, C.A., on March 23, 2026.
  • Reported no revenue for fiscal years ended December 31, 2025 and 2024.
  • Operating expenses were $171,852 in 2025, down from $3,297,858 in 2024.
  • Auditor expressed substantial doubt about the company's ability to continue as a going concern.
  • Common stock traded on OTCQB, with a 450-for-1 reverse split in October 2024.
CCTC
Catalyst Crew Technologies Corp.

Price Impact